FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Nathan Berger

Research Profile

Chemicals & Drugs

Living Beings

Anatomy

Physiology

Disorders

Co-author Network

Publications

TOP 3
Neal J Meropol; Nathan A Berger
Colon cancer recurrence: insights from the interface between epidemiology, laboratory science, and clinical medicine.
Stephen D Hursting; Madhuri Kakarala; Derek LeRoith; Maria Azrad; Angela Brodie; Andrew J Dannenberg; Wendy Demark-Wahnefried; John Digiovanni; Nathan A Berger
Obesity, energy balance, and cancer: new opportunities for prevention.
Cheryl L Thompson; Nathan A Berger; Amitabh Chak; Li Li
Racial differences in measures of obesity and risk of colon adenoma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Nathan Berger (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Neal J Meropol; Nathan A Berger
Colon cancer recurrence: insights from the interface between epidemiology, laboratory science, and clinical medicine.
Journal of the National Cancer Institute 2012;104(22):1697-8.
2012: Stephen D Hursting; Madhuri Kakarala; Derek LeRoith; Maria Azrad; Angela Brodie; Andrew J Dannenberg; Wendy Demark-Wahnefried; John Digiovanni; Nathan A Berger
Obesity, energy balance, and cancer: new opportunities for prevention.
Cancer prevention research (Philadelphia, Pa.) 2012;5(11):1260-72.
2012: Cheryl L Thompson; Nathan A Berger; Amitabh Chak; Li Li
Racial differences in measures of obesity and risk of colon adenoma.
Obesity (Silver Spring, Md.) 2012;20(3):673-7.
2012: Lyla Blake-Gumbs; Zhengyi Chen; Cheryl L Thompson; Thomas C Tucker; Nathan A Berger; Li Li
Adult BMI Change and Risk of Colon Cancer in Postmenopausal Women.
Journal of obesity 2012;2012():857510.
2011: Cheryl L Thompson; Emma K Larkin; Sanjay Patel; Nathan A Berger; Susan Redline; Li Li
Short duration of sleep increases risk of colorectal adenoma.
Cancer 2011;117(4):841-7.
2010: Allison R Weiss; Nathan L Johnson; Nathan A Berger; Susan Redline
Validity of activity-based devices to estimate sleep.
Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2010;6(4):336-42.
2009: Tanyanika Phillips Towe; Elizabeth O'toole; Kathryn Engelhardt; Govardhanan Nagaiah; Nathan A Berger
Changing healthcare practice for older adults with late-stage non-small cell lung cancer: practical considerations of targeted therapy in primary care and oncology.
Journal of the American Geriatrics Society 2009;57 Suppl 2():S253-8.
2009: Julia H Rose; Elizabeth E O'Toole; Siran M Koroukian; Nathan A Berger
Geriatric oncology and primary care: promoting partnerships in practice and research.
Journal of the American Geriatrics Society 2009;57 Suppl 2():S235-8.
2009: Annie E Hill-Baskin; Maciej M Markiewski; David A Buchner; Haifeng Shao; David DeSantis; Gene Hsiao; Shankar Subramaniam; Nathan A Berger; Colleen Croniger; John D Lambris; Joseph H Nadeau
Diet-induced hepatocellular carcinoma in genetically predisposed mice.
Human molecular genetics 2009;18(16):2975-88.
2008: Kara L. Hall; Daniel Stokols; Richard P Moser; Brandie K Taylor; Mark D Thornquist; Linda Nebeling; Carolyn C Ehret; Matthew J Barnett; Anne McTiernan; Nathan A Berger; Michael I Goran; Robert W Jeffery
The collaboration readiness of transdisciplinary research teams and centers findings from the National Cancer Institute's TREC Year-One evaluation study.
American journal of preventive medicine 2008;35(2 Suppl):S161-72.
2008: Nora L Nock; Cheryl L Thompson; Thomas C Tucker; Nathan A Berger; Li Li
Associations between obesity and changes in adult BMI over time and colon cancer risk.
Obesity (Silver Spring, Md.) 2008;16(5):1099-104.
2008: Cheryl L Thompson; Vijay Khiani; Amitabh Chak; Nathan A Berger; Li Li
Carbohydrate consumption and esophageal cancer:an ecological assessment.
The American journal of gastroenterology 2008;103(3):555-61.
2006: Nathan A Berger; Panos Savvides; Siran M Koroukian; Eva F Kahana; Gary T Deimling; Julia H Rose; Karen F Bowman; Robert H Miller
Cancer in the elderly.
Transactions of the American Clinical and Climatological Association 2006;117():147-55; discussion 155-6.
2004: Min Li; Padmavathy Naidu; Yihong Yu; Nathan A Berger; Perry Kannan
Dual regulation of AP-2alpha transcriptional activation by poly(ADP-ribose) polymerase-1.
The Biochemical journal 2004;382(Pt 1):323-9.
2002: Haruyo Hirota; David Gosky; Nathan A Berger; Satadal Chatterjee
Interference with topoisomerase IIalpha potentiates melphalan cytotoxicity.
International journal of oncology 2002;20(2):311-8.
2001: Afshin Dowlati; John R Haaga; Scot C Remick; Timothy P Spiro; Stanton L Gerson; Lili Liu; Sosamma J Berger; Nathan A Berger; James Willson
Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(10):2971-6.
2001: Afshin Dowlati; Nathan Levitan; Nahida H Gordon; Charles L Hoppel; David Gosky; Scot C Remick; Stephen T Ingalls; Sosamma J Berger; Nathan A Berger
Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer.
Cancer chemotherapy and pharmacology 2001;47(2):141-8.
2000: Chris H Takimoto; Geraldine Morrison; Nancy Harold; Mary Quinn; Brian P Monahan; RA Band; John R Cottrell; A Guemei; Victor Llorens; H Hehman; Abdel-Salam Attia Ismail; D Flemming; David Gosky; H Hirota; Sosamma J Berger; Nathan A Berger; Alice P Chen; JD Shapiro; Arbuck Susan; J Wright; J Michael Hamilton; Carmen J Allegra; Jean L Grem
Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(3):659-67.
1999: CA Belfi; Satadal Chatterjee; David Gosky; Sosamma J Berger; Nathan A Berger
Increased sensitivity of human colon cancer cells to DNA cross-linking agents after GRP78 up-regulation.
Biochemical and biophysical research communications 1999;257(2):361-8.
1999: Satadal Chatterjee; Sosamma J Berger; Nathan A Berger
Poly(ADP-ribose) polymerase: a guardian of the genome that facilitates DNA repair by protecting against DNA recombination.
Molecular and cellular biochemistry 1999;193(1-2):23-30.
1999: Cecilia M Whitacre; Elizabeth Zborowska; James Willson; Nathan A Berger
Detection of poly(ADP-ribose) polymerase cleavage in response to treatment with topoisomerase I inhibitors: a potential surrogate end point to assess treatment effectiveness.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(3):665-72.
1998: Johannes Grossmann; J M Maxson; Cecilia M Whitacre; D E Orosz; Nathan A Berger; Claudio Fiocchi; Alan D Levine
New isolation technique to study apoptosis in human intestinal epithelial cells.
The American journal of pathology 1998;153(1):53-62.
1998: Karen S McColl; Huiling He; H Zhong; Cecilia M Whitacre; Nathan A Berger; Clark W Distelhorst
Apoptosis induction by the glucocorticoid hormone dexamethasone and the calcium-ATPase inhibitor thapsigargin involves Bc1-2 regulated caspase activation.
Molecular and cellular endocrinology 1998;139(1-2):229-38.
1998: J He; Cecilia M Whitacre; Liang-yan Xue; Nathan A Berger; Nancy L Oleinick
Protease activation and cleavage of poly(ADP-ribose) polymerase: an integral part of apoptosis in response to photodynamic treatment.
Cancer research 1998;58(5):940-6.
1997: Satadal Chatterjee; H Hirota; CA Belfi; Sosamma J Berger; Nathan A Berger
Hypersensitivity to DNA cross-linking agents associated with up-regulation of glucose-regulated stress protein GRP78.
Cancer research 1997;57(22):5112-6.
1997: Cecilia M Whitacre; Nathan A Berger
Factors affecting topotecan-induced programmed cell death: adhesion protects cells from apoptosis and impairs cleavage of poly(ADP-ribose)polymerase.
Cancer research 1997;57(11):2157-63.
1997: Cecilia M Whitacre; Elizabeth Zborowska; Nahida H Gordon; Wilma Mackay; Nathan A Berger
Topotecan increases topoisomerase IIalpha levels and sensitivity to treatment with etoposide in schedule-dependent process.
Cancer research 1997;57(8):1425-8.
1996: Nathan A Berger
Alkylating agents.
Cancer chemotherapy and biological response modifiers 1996;16():28-38.
1995: J S Masin; Sosamma J Berger; S Setrakian; D W Stepnick; Nathan A Berger
Topoisomerase I activity in squamous cell carcinoma of the head and neck.
The Laryngoscope 1995;105(11):1191-6.
1995: H Hashimoto; Satadal Chatterjee; Nathan A Berger
Inhibition of etoposide (VP-16)-induced DNA recombination and mutant frequency by Bcl-2 protein overexpression.
Cancer research 1995;55(18):4029-35.
1995: Cecilia M Whitacre; H Hashimoto; M L Tsai; Satadal Chatterjee; Sosamma J Berger; Nathan A Berger
Involvement of NAD-poly(ADP-ribose) metabolism in p53 regulation and its consequences.
Cancer research 1995;55(17):3697-701.
1995: Satadal Chatterjee; M F Cheng; R B Berger; Sosamma J Berger; Nathan A Berger
Effect of inhibitors of poly(ADP-ribose) polymerase on the induction of GRP78 and subsequent development of resistance to etoposide.
Cancer research 1995;55(4):868-73.
1995: G B Ranjit; M F Cheng; W Mackay; Cecilia M Whitacre; J S Berger; Nathan A Berger
Poly(adenosine diphosphoribose) polymerase in peripheral blood leukocytes from normal donors and patients with malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(2):223-34.
1995: S Hashimoto; Satadal Chatterjee; G B Ranjit; C Bao; J Ford; R Ganapathi; Sosamma J Berger; Nathan A Berger
Drastic reduction of topoisomerase II alpha associated with major acquired resistance to topoisomerase II active agents but minor perturbations of cell growth.
Oncology research 1995;7(7-8):407-16.
1995: Nathan A Berger; Cecilia M Whitacre; H Hashimoto; Sosamma J Berger; Satadal Chatterjee
NAD and poly(ADP-ribose) regulation of proteins involved in response to cellular stress and DNA damage.
Biochimie 1995;77(5):364-7.
1995: S Hashimoto; M K Danks; Satadal Chatterjee; William T Beck; Nathan A Berger
A novel point mutation in the 3' flanking region of the DNA-binding domain of topoisomerase II alpha associated with acquired resistance to topoisomerase II active agents.
Oncology research 1995;7(1):21-9.
1994: Satadal Chatterjee; Nathan A Berger
Growth-phase-dependent response to DNA damage in poly(ADP-ribose) polymerase deficient cell lines: basis for a new hypothesis describing the role of poly(ADP-ribose) polymerase in DNA replication and repair.
Molecular and cellular biochemistry 1994;138(1-2):61-9.
1994: Satadal Chatterjee; M F Cheng; Sosamma J Berger; Nathan A Berger
Induction of M(r) 78,000 glucose-regulated stress protein in poly(adenosine diphosphate-ribose) polymerase- and nicotinamide adenine dinucleotide-deficient V79 cell lines and its relation to resistance to the topoisomerase II inhibitor etoposide.
Cancer research 1994;54(16):4405-11.
1994: Sosamma J Berger; D Gosky; Elizabeth Zborowska; James Willson; Nathan A Berger
Sensitive enzymatic cycling assay for glutathione: measurements of glutathione content and its modulation by buthionine sulfoximine in vivo and in vitro in human colon cancer.
Cancer research 1994;54(15):4077-83.
1994: M F Cheng; Satadal Chatterjee; Nathan A Berger
Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens.
Oncology research 1994;6(6):269-79.
1994: Nathan A Berger
Alkylating agents.
Cancer chemotherapy and biological response modifiers 1994;15():32-43.
1993: Nathan A Berger
Alkylating agents.
Cancer chemotherapy and biological response modifiers 1993;14():26-36.
1992: Stanton L Gerson; Nathan A Berger; C Arce; S J Petzold; James Willson
Modulation of nitrosourea resistance in human colon cancer by O6-methylguanine.
Biochemical pharmacology 1992;43(5):1101-7.
1991: Nathan A Berger; Satadal Chatterjee; J A Schmotzer; S R Helms
Etoposide (VP-16-213)-induced gene alterations: potential contribution to cell death.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(19):8740-3.
1991: Satadal Chatterjee; M F Cheng; Sosamma J Berger; Nathan A Berger
Alkylating agent hypersensitivity in poly(adenosine diphosphate-ribose) polymerase deficient cell lines.
Cancer communications 1991;3(3):71-5.
1990: Satadal Chatterjee; D Trivedi; S J Petzold; Nathan A Berger
Mechanism of epipodophyllotoxin-induced cell death in poly(adenosine diphosphate-ribose) synthesis-deficient V79 Chinese hamster cell lines.
Cancer research 1990;50(9):2713-8.
1990: Satadal Chatterjee; M F Cheng; Nathan A Berger
Hypersensitivity to clinically useful alkylating agents and radiation in poly(ADP-ribose) polymerase-deficient cell lines.
Cancer communications 1990;2(12):401-7.
1989: Satadal Chatterjee; N V Hirschler; S J Petzold; S J Berger; Nathan A Berger
Mutant cells defective in poly(ADP-ribose) synthesis due to stable alterations in enzyme activity or substrate availability.
Experimental cell research 1989;184(1):1-15.
1989: T R Spitzer; Hillard M Lazarus; R J Creger; Nathan A Berger
High-dose melphalan, misonidazole, and autologous bone marrow transplantation for the treatment of metastatic colorectal carcinoma. A phase I study.
American journal of clinical oncology 1989;12(2):145-51.
1989: C A Spiridonidis; Satadal Chatterjee; S J Petzold; Nathan A Berger
Topoisomerase II-dependent and -independent mechanisms of etoposide resistance in Chinese hamster cell lines.
Cancer research 1989;49(3):644-50.
1989: Satadal Chatterjee; M F Cheng; D Trivedi; S J Petzold; Nathan A Berger
Camptothecin hypersensitivity in poly(adenosine diphosphate-ribose) polymerase-deficient cell lines.
Cancer communications 1989;1(6):389-94.
1988: Hillard M Lazarus; Nathan A Berger
Chemotherapy of malignant disease: an update.
Comprehensive therapy 1988;14(5):56-63.
1988: Nathan A Berger; N Hirschler
Therapeutic strategies for cancer chemotherapy based on metabolic consequences of DNA damage.
Annals of the New York Academy of Sciences 1988;551():415-8; discussion 419-20.
1987: Nathan A Berger; S J Berger; Stanton L Gerson
DNA repair, ADP-ribosylation and pyridine nucleotide metabolism as targets for cancer chemotherapy.
Anti-cancer drug design 1987;2(2):203-9.
1987: Satadal Chatterjee; S J Petzold; S J Berger; Nathan A Berger
Strategy for selection of cell variants deficient in poly(ADP-ribose) polymerase.
Experimental cell research 1987;172(2):245-57.
1985: Nathan A Berger; S J Petzold
Identification of minimal size requirements of DNA for activation of poly(ADP-ribose) polymerase.
Biochemistry 1985;24(16):4352-5.
1985: Nathan A Berger; S J Berger; D M Catino; S J Petzold; R K Robins
Modulation of nicotinamide adenine dinucleotide and poly(adenosine diphosphoribose) metabolism by the synthetic "C" nucleoside analogs, tiazofurin and selenazofurin. A new strategy for cancer chemotherapy.
The Journal of clinical investigation 1985;75(2):702-9.
1983: J L Sims; S J Berger; Nathan A Berger
Poly(ADP-ribose) Polymerase inhibitors preserve nicotinamide adenine dinucleotide and adenosine 5'-triphosphate pools in DNA-damaged cells: mechanism of stimulation of unscheduled DNA synthesis.
Biochemistry 1983;22(22):5188-94.
1983: Nathan A Berger; J L Sims; D M Catino; S J Berger
Poly(ADP-ribose) polymerase mediates the suicide response to massive DNA damage: studies in normal and DNA-repair defective cells.
Princess Takamatsu symposia 1983;13():219-26.
1982: Nathan A Berger; D M Catino; T J Vietti
Synergistic antileukemic effect of 6-aminonicotinamide and 1,3-bis(2-chloroethyl)-1-nitrosourea on L1210 cells in vitro and in vivo.
Cancer research 1982;42(11):4382-6.
1982: J J Cohen; D M Catino; S J Petzold; Nathan A Berger
Activation of poly(adenosine diphosphate ribose) polymerase by SV 40 minichromosomes: effects of deoxyribonucleic acid damage and histone H1.
Biochemistry 1982;21(20):4931-40.
1982: Nathan A Berger; S J Berger; D M Catino
Abnormal NAD+ levels in cells from patients with Fanconi's anaemia.
Nature 1982;299(5880):271-3.
1982: J L Sims; G W Sikorski; D M Catino; S J Berger; Nathan A Berger
Poly(adenosinediphosphoribose) polymerase inhibitors stimulate unscheduled deoxyribonucleic acid synthesis in normal human lymphocytes.
Biochemistry 1982;21(8):1813-21.
1982: Nathan A Berger; S J Berger; G W Sikorski; D M Catino
Amplification of pyridine nucleotide pools in mitogen-stimulated human lymphocytes.
Experimental cell research 1982;137(1):79-88.
1981: S J Petzold; B A Booth; G A Leimbach; Nathan A Berger
Purification and properties of poly(ADP-ribose) polymerase from lamb thymus.
Biochemistry 1981;20(25):7075-81.
1981: Nathan A Berger; G W Sikorski
Poly(adenosine diphosphoribose) synthesis in ultraviolet-irradiated xeroderma pigmentosum cells reconstituted with Micrococcus luteus UV endonuclease.
Biochemistry 1981;20(12):3610-4.
1981: J L Sims; S J Berger; Nathan A Berger
Effects of nicotinamide on NAD and poly(ADP-ribose) metabolism in DNA-damaged human lymphocytes.
Journal of supramolecular structure and cellular biochemistry 1981;16(3):281-8.
1980: Nathan A Berger; G W Sikorski
Nicotinamide stimulates repair of DNA damage in human lymphocytes.
Biochemical and biophysical research communications 1980;95(1):67-72.
1980: Nathan A Berger; G W Sikorski; S J Petzold; K K Kurohara
Defective poly(adenosine diphosphoribose) synthesis in xeroderma pigmentosum.
Biochemistry 1980;19(2):289-93.